Meeting
2015 Gastrointestinal Cancers Symposium
Nab-paclitaxel (Nab-P) and gemcitabine (G) as first-line chemotherapy (CT) in advanced pancreatic cancer (APDAC) elderly patients (pts): A “real-life” study.
Authors
Guido Giordano
Medical Oncology Unit, Ospedale Sacro Cuore di Gesù, Fatebenefratelli,, Benevento, Italy
Guido Giordano , Vanja Vaccaro , Eleonora Lucchini , Gianna Musettini , Paola Bertocchi , Francesca Bergamo , Elisa Giommoni , Matteo Santoni , Marco Russano , Serena Campidoglio , Daniele Santini , Alberto Zaniboni , Vittorina Zagonel , Stefano Cascinu , Enrico Vasile , Davide Melisi , Michele Milella , Antonio Febbraro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 424)
DOI
10.1200/jco.2015.33.3_suppl.424
Abstract #
424
Poster Bd #
D43
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of the third-line chemotherapy in patients with advanced pancreatic cancer.
First Author: Bomi Kim
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First-line chemotherapy regimens associated with survival in advanced pancreatic cancer: A Mexican single-center, real-world study.
First Author: Marytere Herrera
Poster
2021 Gastrointestinal Cancers Symposium
Genomic biomarker discovery of first-line gemcitabine/nabpaclitaxel treatment in Chinese advanced pancreatic carcinoma patients.
First Author: Juan Du
Poster
2017 Gastrointestinal Cancers Symposium
Nab-paclitaxel (Nab-P) and gemcitabine (G) first-line chemotherapy (CT) in patients (pts) with metastatic pancreatic cancer (mPC) who relapsed after adjuvant treatment (ADJ T): A “REAL LIFE” study.
First Author: Guido Giordano